Corrigendum: Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma.
Frontiers in oncology（2023）
摘要
[This corrects the article DOI: 10.3389/fonc.2022.979519.].
更多查看译文
关键词
endometrial cancer,immune response,lenvatinib,pembrolizumab,tyrosine kinase inhibitor
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要